Logo KMS TEAM
Precise execution

MC Services is...

Client News

 

 

… an international Corporate Communications and Investor Relations firm providing high-level consultancy with targeted services and support for transaction-oriented assignments throughout Europe and the United States.

 

read more

 

MC Services hosted Press Lounge at the BIO-Europe 2016 in Cologne

 

This fall, Cologne hosted Europe’s largest partnering conference for the global biotechnology industry - BIO-Europe®. The event took place November 7-9 and had over 3,600 attendees from over 60 countries. MC Services was supporting BIO-Europe® as media partner and hosted the new conference Press Lounge: Centrally located in the exhibit hall – in the midst of activities – journalists were able to retreat to a quiet, fully-equipped work station or use the lounge area to conduct interviews or network with industry representatives.
 

Twitter: #BIOEurope 2016 #PressLounge

 

MC Services, EBD Group, BIO.NRW and LaBiotech.eu joined forces for BIO-Europe 2016 live blog

 

MC Services led a joint initiative with EBD Group, BIO.NRW LaBiotech.eu at BIO-Europe to introduce science journalist students from the “Kölner Journalistenschule” and the TU Dortmund to the biosciences industry. The students were invited to BIO-Europe to conduct interviews with participants and report their impressions of the event, as well as highlights from panels, company presentations and discussions. This content is available in a blog, designed for experts and generalists alike, with the aim of connecting the conference with international audiences and relevant local communities.

 

Please also follow us on Twitter (@MCServicesAG; #BIOEurope 2016)

 

The blog is available here

 

MC Services introduces “BIT” - the BIO-Europe® Investor Talks


During the course of the BIO-Europe 2016, MC Services conducted video interviews with some of the most prominent European investors/VCs in the life sciences space to capture their thoughts on current and future trends in the sector, how the investors are addressing these trends and what exit paths they are realistically seeing in Europe.

 

The interviews are available here

UC Davis to Conduct Phase 2 Trial of the Combination of TG4010 with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)

www.transgene.fr

Innovative Phase II study design of Glutaminylcyclase Inhibitor PQ912 in early Alzheimer’s disease

www.probiodrug.de

Planned Management Team Changes

www.kiadis.com

AYOXXA appoints permanent CEO

www.ayoxxa.com

ABIVAX provides update on clinical development program for ABX464 for functional cure of patients with HIV-infection

www.abivax.com/en

Neovacs obtains FDA "Fast Track" designation for IFNα Kinoid in Lupus (SLE)

www.neovacs.fr

Medigene AG to be included in TecDAX Index

www.medigene.com

Kiadis Pharma presents positive 1-year follow-up data of its pivotal Phase II trial with ATIR101™

www.kiadis.com

MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 2016 Conference

www.morphosys.com

TÜV gives clearance to start operations in the Leuna Demo Plant

www.global-bioenergies.com

Apogenix Reports Final Phase I MDS Data at this Year´s American Society of Hematology (ASH) Meeting

www.apogenix.com

PUBLICATION OF CIRCULAR AND NOTICE OF GENERAL MEETING 

www.motifbio.com